Stomach Flashcards
Blood supply of the stomach?
Greater curvature (L gastroepiploic via splenic artery, R gastroepiploic via GDA), lesser curvature (L gastric via celiac trunk, R gastric via common hepatic artery)
Cells in the stomach? What do they secrete? (Mucus, chief, parietal, G cells, D cells)
Mucus, chief - pepsinogen (1st enzyme of proteolysis), parietal - H+, intrinsic factor, G cells - gastrin (inhibited by H+ in duodenum, stimulated by amino acids and Ach), D cells - somatostatin (inhibits gastrin and acid release)
What stimulates acid secretion? What suppresses acid secretion?
stimulated by Ach via vagus nerve, gastrin, and histamine, suppressed by somatostatin, PGE1, secretin, CCK
Mechanism of omeprazole?
Blocks H+/K+ ATPase in parietal cell membrane (final pathway for H+ release)
Cellular pathway of acetylcholine, gastrin, histamine?
Acetylcholine and gastrin activate phospholipase (PIP -> DAG + IP3 to increase Ca+, which activates phosphorylase kinase, causing H+ release); histamine activates cAMP, activates protein kinase A which leads to H+ release
What is intrinsic factor?
Helps with absorption of vitamin b12 by binding to it, produced by parietal cells; the complex is reabsorbed in the terminal ileum
What are Brunner’s glands?
Located in the duodenum, they secrete alkaline mucus
What are dieulafoy’s ulcers?
Congenital vascular malformation typically on lesser curvature, submucosal artery that is abnormally large and tortuous, can bleed - tx w/ endoscopy, cautery, sclerosing
What is Menetrier’s disease?
Mucous cell hyperplasia, increased rugal folds, loss of parietal cells leading to achlorhydria, loss protein in stomach due to mucous hyper secretion, increased gastric Ca risk high protein diet, anticholinergic agents, Cetuximab (growth factor alpha blocker) is promising tx
Gastric volvulus: primary/secondary, axis, symptoms, treatment?
Primary (idiopathic), secondary occurs in 2/3 due to anatomical problem like paraesophageal hernia / diaphragmatic hernia, etc; usually organoaxial volvulus (long axis) antrum antero-superior, fundus postero-inferior, often assoc. w/ anatomic problem – mesenteroaxial volvulus (short axis) usually not associated with secondary anatomic defect – Tx w/ NG, endoscopic detorsion, surgery (reduction/fundoplication) vs gastric fixation via G-tube
Treatment for mallory-weiss tear
EGD with clips, tear usually on lesser curvature near GE junction
What is the most common side effect after vagotomy and what is the pathophysiology?
Diarrhea (40% of patients), caused by sustained migrating motor complexes forcing bile acids into the colon
Types of gastric ulcers?
type I = distal lesser curve (most common) - decreased/normal acid production, type II = 2 ulcers, lesser curve and duodenal - high acid production, type III = pre-pyloric ulcer - high acid production, type IV = lesser curve high/proximal/GE junction - normal/low acid production – impaired mucosal defense, V = associated with NSAIDs – “4+1 = 3+2 = 5” in order from proximal to distal
Periop chemo regimen for gastric cancer?
Based off of MAGIC trial - ECF, epirubicin, cisplatin, and fluorouracil
stomach GIST: dx, path, treatment?
most common benign gastric neoplasms, arises from mesenchymal / Cajal cells – not smooth muscle!, if malignant spreads hematogenously, usually asymptomatic, hyperechoic on ultrasound w/ smooth edges, dx w/ biopsy shows C-kit positive, +Cd117 stain – would be concerned if large (>5 cm or >5 mitoses/50 HPF), resect with 1 cm margins (microscopic positive margins do not affect survival), chemo w/ imatinib (Gleevec, tyrosine kinase inhibitor)
MALT lymphoma: underlying problem? tx?
related to h. pylori, infection induces a lymphoid infiltrate, B cell proliferation occurs; usually regresses within 1 yr after treatment for H. pylori, XRT if fails after 1 yr (CHOP - cyclophosphamide, doxorubicin, vincristine, prednisone) – 11;18 translocation are unlikely to respond w/ just H. pylori eradication
Gastric lymphoma: most common type? dx? tx?
most commonly B-cell NHL; dx w/ EGD w/ biopsy, chemo/XRT primary treatment modalities
NIH criteria for bariatric surgery
BMI >40 (or BMI >35 w/ coexisting comorbidities), failure of nonsurgical methods, psychologic stability, absence of drug/EtOH use